Previous 10 | Next 10 |
2024-02-08 06:48:31 ET Summary BRIUMVI sets the standard for CD20 administration with efficient twice-yearly 1-hour infusions. BRIUMVI should remain competitive with subcutaneous formulations. Whether or not BTKIs erode the long-term market for CD20s in coming years remains to...
2024-02-07 09:52:29 ET More on MorphoSys Novartis And MorphoSys Are A Perfect Match MorphoSys: Positive Pelabresib Data Finally Unlocking Upside MorphoSys: A Buying Opportunity Following Mixed Phase 3 Results In Myelofibrosis MorphoSys drops amid speculation ...
2024-02-06 17:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-06 12:21:34 ET More on MorphoSys Novartis And MorphoSys Are A Perfect Match MorphoSys: Positive Pelabresib Data Finally Unlocking Upside MorphoSys: A Buying Opportunity Following Mixed Phase 3 Results In Myelofibrosis Incyte buys global rights for taf...
2024-02-06 08:00:00 ET Summary Novartis plans to acquire MorphoSys, a German biopharmaceutical company, for EUR 2.7 billion in cash. The acquisition will give Novartis access to MorphoSys' extensive oncological pipeline, including the potentially game-changing treatment option for...
2024-02-05 17:52:08 ET More on Incyte Incyte: Overly Reliant On Jakafi Despite Positive Phase 2 Results For Axatilimab Agilent, Incyte to collaborate on companion diagnostics development Why did Incyte stock go up today? Positive drug study Seeking Alpha ...
2024-02-05 17:02:22 ET Novartis ( NYSE: NVS ) said it will acquire cancer drugmake r MorphoSys AG ( MOR ) for EUR 68/share, or an aggregate of EUR 2.7B.... Read the full article on Seeking Alpha For further details see: Novartis to buy cancer drugmaker Mo...
2024-02-05 16:32:27 ET More on Cytokinetics Cytokinetics Steps Up As Prime Target After Aficamten's HCM Triumph (Rating Upgrade) Cytokinetics: Clear Win For Aficamten In SEQUOIA-HCM Phase 3 Trial (Upgrade) Cytokinetics: Buyout Rumors Ahead Of The Key Phase 3 Readout ...
2024-02-05 10:24:24 ET More on MorphoSys MorphoSys: Positive Pelabresib Data Finally Unlocking Upside MorphoSys: A Buying Opportunity Following Mixed Phase 3 Results In Myelofibrosis MorphoSys: Buying Constellation Was A Desperate Measure MorphoSys expects 20...
2024-02-04 05:50:00 ET Any time is a good time to buy solid dividend stocks. But this month is a special time to do so for one simple reason: There's an extra day for investors to buy stocks because it's a leap year. Three Motley Fool contributors have picked what they believe are fabul...
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 04:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-18 16:45:16 ET Image source: The Motley Fool. Novartis Ag (NYSE: NVS) Q2 2024 Earnings Call Jul 18, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
2024-07-18 14:15:34 ET By most standards shares of drugmaker Novartis (NYSE: NVS) should be higher following this morning's release of its second-quarter results. The drugmaker's top and bottom lines were both better than expected, and up from year-earlier comparisons. And profit gu...